On this interview with Andrew Kleuss on Buyers Hub, Vitaliy makes the case that considerations over Amazon’s entry into the prescription drugs enterprise are most likely overblown. To parse this downside, Vitaliy differentiates between pharmacies and drug distributors, and analyzes the extent to which Amazon can compete with each. Whereas Amazon may place some stress on pharmacies over time, he explains how drug distributors’ distinctive provide chains ought to stay strong in opposition to a aggressive risk from Amazon.